4CPS-159 Quality of life assessment and efficacy of secukinumab in plaque psoriasis disease

BACKGROUND: Secukinumab has demonstrated efficacy in moderate to severe plaque psoriasis (PP) by improving the Psoriasis Area and Severity Index (PASI), but patients’ quality of life is not always quantified in clinical trials. PURPOSE: To evaluate the efficacy of secukinumab in PP treatment and how...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Eur J Hosp Pharm
Hlavní autoři: Ruiz, M Pedrosa, Carmona, I Moya, Yañez, E Sanchez, Ovies, JM Fernandez
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2018
Témata:
Section 4: Clinical pharmacy services
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535509/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.250
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky